Photo taken from Manish A. Shah/X
Jul 7, 2024, 14:48
Analysis of CLDN18.2 expression in gastric and GEJ cancers
Manish A. Shah, Director of the Gastrointestinal Oncology Program at Weill Cornell Medical College, shared on X:
“Happy to report our analysis of CLDN18.2 expression globally! Important for those who will receive CLDN18.2 targeted Rx for gastric and gastroesophageal junction cancers!
Zolbetuximab is already approved in Japan! Hopefully we’ll have access soon! ”
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
Source: Manish A. Shah/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14